PortalPublikationenA pre-specified model based on four kallikrein markers in bl...

A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy

Standard

A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. / Haese, Alexander; Tin, Amy L; Carlsson, Sigrid V; Sjoberg, Daniel D; Pehrke, Dirk; Steuber, Thomas; Huland, Hartwig; Graefen, Markus; Scardino, Peter T; Schlomm, Thorsten; Vickers, Andrew J; Lilja, Hans; Sauter, Guido.

in: BRIT J CANCER, Jahrgang 123, Nr. 4, 08.2020, S. 604-609.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Haese, A, Tin, AL, Carlsson, SV, Sjoberg, DD, Pehrke, D, Steuber, T, Huland, H, Graefen, M, Scardino, PT, Schlomm, T, Vickers, AJ, Lilja, H & Sauter, G 2020, 'A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy', BRIT J CANCER, Jg. 123, Nr. 4, S. 604-609. https://doi.org/10.1038/s41416-020-0914-7

APA

Haese, A., Tin, A. L., Carlsson, S. V., Sjoberg, D. D., Pehrke, D., Steuber, T., Huland, H., Graefen, M., Scardino, P. T., Schlomm, T., Vickers, A. J., Lilja, H., & Sauter, G. (2020). A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. BRIT J CANCER, 123(4), 604-609. https://doi.org/10.1038/s41416-020-0914-7

Vancouver

Haese A, Tin AL, Carlsson SV, Sjoberg DD, Pehrke D, Steuber T et al. A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. BRIT J CANCER. 2020 Aug;123(4):604-609. https://doi.org/10.1038/s41416-020-0914-7

Bibtex

@article{604c7ed1f8974247b0240a5f22350e09,
title = "A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy",
abstract = "BACKGROUND: A pre-specified model based on four kallikrein markers in blood, commercially available as 4Kscore, predicts Gleason Grade (GG) 3 + 4 or higher prostate cancer on biopsy. However, sampling error and variation in pathology reporting may miss aggressive disease.METHODS: The 4Kscore was measured in cryopreserved blood from 2330 men obtained before prostatectomy at a single institution between 2002 and 2010. Adverse surgical pathology and biochemical recurrence (BCR) were pre-specified to be assessed in all men, biopsy GG 3 + 3, and 3 + 4.RESULTS: Adjusted for established clinical predictors, the 4Kscore was significantly associated with adverse pathology (OR 1.49; 95% CI 1.32, 1.67; p < 0.0001). Adding 4Kscore increased discrimination from (AUC) 0.672 to 0.718 and 0.644 to 0.659 within biopsy GG 3 + 3 and 3 + 4, respectively. Higher 4Kscore was associated with higher risk of BCR (HR 1.16, 95% CI 1.06, 1.26; p = 0.001). Adding 4Kscore improved the prediction of BCR (C-index 0.630-0.660) within GG 3 + 3, but not GG 3 + 4.CONCLUSIONS: The 4Kscore can help guide the clinical decision whether additional risk assessment-such as confirmatory biopsy-is needed to decide between active surveillance versus curative therapy. Evidence that the panel could influence management in biopsy GG 3 + 4 is less strong and requires further investigation.",
author = "Alexander Haese and Tin, {Amy L} and Carlsson, {Sigrid V} and Sjoberg, {Daniel D} and Dirk Pehrke and Thomas Steuber and Hartwig Huland and Markus Graefen and Scardino, {Peter T} and Thorsten Schlomm and Vickers, {Andrew J} and Hans Lilja and Guido Sauter",
year = "2020",
month = aug,
doi = "10.1038/s41416-020-0914-7",
language = "English",
volume = "123",
pages = "604--609",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "4",

}

RIS

TY - JOUR

T1 - A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy

AU - Haese, Alexander

AU - Tin, Amy L

AU - Carlsson, Sigrid V

AU - Sjoberg, Daniel D

AU - Pehrke, Dirk

AU - Steuber, Thomas

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Scardino, Peter T

AU - Schlomm, Thorsten

AU - Vickers, Andrew J

AU - Lilja, Hans

AU - Sauter, Guido

PY - 2020/8

Y1 - 2020/8

N2 - BACKGROUND: A pre-specified model based on four kallikrein markers in blood, commercially available as 4Kscore, predicts Gleason Grade (GG) 3 + 4 or higher prostate cancer on biopsy. However, sampling error and variation in pathology reporting may miss aggressive disease.METHODS: The 4Kscore was measured in cryopreserved blood from 2330 men obtained before prostatectomy at a single institution between 2002 and 2010. Adverse surgical pathology and biochemical recurrence (BCR) were pre-specified to be assessed in all men, biopsy GG 3 + 3, and 3 + 4.RESULTS: Adjusted for established clinical predictors, the 4Kscore was significantly associated with adverse pathology (OR 1.49; 95% CI 1.32, 1.67; p < 0.0001). Adding 4Kscore increased discrimination from (AUC) 0.672 to 0.718 and 0.644 to 0.659 within biopsy GG 3 + 3 and 3 + 4, respectively. Higher 4Kscore was associated with higher risk of BCR (HR 1.16, 95% CI 1.06, 1.26; p = 0.001). Adding 4Kscore improved the prediction of BCR (C-index 0.630-0.660) within GG 3 + 3, but not GG 3 + 4.CONCLUSIONS: The 4Kscore can help guide the clinical decision whether additional risk assessment-such as confirmatory biopsy-is needed to decide between active surveillance versus curative therapy. Evidence that the panel could influence management in biopsy GG 3 + 4 is less strong and requires further investigation.

AB - BACKGROUND: A pre-specified model based on four kallikrein markers in blood, commercially available as 4Kscore, predicts Gleason Grade (GG) 3 + 4 or higher prostate cancer on biopsy. However, sampling error and variation in pathology reporting may miss aggressive disease.METHODS: The 4Kscore was measured in cryopreserved blood from 2330 men obtained before prostatectomy at a single institution between 2002 and 2010. Adverse surgical pathology and biochemical recurrence (BCR) were pre-specified to be assessed in all men, biopsy GG 3 + 3, and 3 + 4.RESULTS: Adjusted for established clinical predictors, the 4Kscore was significantly associated with adverse pathology (OR 1.49; 95% CI 1.32, 1.67; p < 0.0001). Adding 4Kscore increased discrimination from (AUC) 0.672 to 0.718 and 0.644 to 0.659 within biopsy GG 3 + 3 and 3 + 4, respectively. Higher 4Kscore was associated with higher risk of BCR (HR 1.16, 95% CI 1.06, 1.26; p = 0.001). Adding 4Kscore improved the prediction of BCR (C-index 0.630-0.660) within GG 3 + 3, but not GG 3 + 4.CONCLUSIONS: The 4Kscore can help guide the clinical decision whether additional risk assessment-such as confirmatory biopsy-is needed to decide between active surveillance versus curative therapy. Evidence that the panel could influence management in biopsy GG 3 + 4 is less strong and requires further investigation.

U2 - 10.1038/s41416-020-0914-7

DO - 10.1038/s41416-020-0914-7

M3 - SCORING: Journal article

C2 - 32467601

VL - 123

SP - 604

EP - 609

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 4

ER -